{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:55:04Z","timestamp":1790096104473,"version":"4.0.1"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T00:00:00Z","timestamp":1745107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.toxrep.2025.102033","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T08:04:48Z","timestamp":1745481888000},"page":"102033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immune checkpoint inhibitors: From friend to foe"],"prefix":"10.1016","volume":"14","author":[{"given":"Prem","family":"Rajak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxrep.2025.102033_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.toxrep.2025.102033_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant Ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.toxrep.2025.102033_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.toxrep.2025.102033_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study","volume":"6","author":"Guida","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.toxrep.2025.102033_bib7","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1200\/JCO.2019.37.15_suppl.2616","article-title":"Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity","volume":"37","author":"Johnson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib8","first-page":"945","article-title":"Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma","volume":"71","author":"Harsch","year":"2018","journal-title":"Wiadomosci Lek."},{"key":"10.1016\/j.toxrep.2025.102033_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib10","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14737140.2022.2094772","article-title":"Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer","volume":"22","author":"Issa","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.toxrep.2025.102033_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib13","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.toxrep.2025.102033_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/biology10060561","article-title":"Rheumatic immune-related adverse events\u2014a consequence of immune checkpoint inhibitor therapy","volume":"10","author":"Bobirc\u0103","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.toxrep.2025.102033_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-015-0442-6","article-title":"Nivolumab: a review in advanced melanoma","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.toxrep.2025.102033_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40265-020-01302-2","article-title":"Cemiplimab: a review in advanced cutaneous squamous cell carcinoma","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.toxrep.2025.102033_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.toxrep.2025.102033_bib19","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.toxrep.2025.102033_bib21","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac019","article-title":"Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor","volume":"2","author":"Schwartz","year":"2022","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.toxrep.2025.102033_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.toxrep.2025.102033_bib24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.toxrep.2025.102033_bib25","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4049\/jimmunol.2200244","article-title":"Inhibition of IL-17A protects against thyroid immune-related adverse events while preserving checkpoint inhibitor antitumor efficacy","volume":"209","author":"Lechner","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib27","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.toxrep.2025.102033_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ijd.13540","article-title":"Supported by GESTIM Nantes group of cutaneous adverse events induced by anticancer drugs, Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma","volume":"56","author":"Perret","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.toxrep.2025.102033_bib29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/cup.13454","article-title":"Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response","volume":"46","author":"Curry","year":"2019","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.toxrep.2025.102033_bib30","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.toxrep.2025.102033_bib31","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.toxrep.2025.102033_bib33","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.toxrep.2025.102033_bib35","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma\u2013producing CD8+\u2009tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor\u2013colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxrep.2025.102033_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/07357907.2017.1324032","article-title":"Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy","volume":"35","author":"Bamias","year":"2017","journal-title":"Cancer Investig."},{"key":"10.1016\/j.toxrep.2025.102033_bib38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"ECCOJC"},{"key":"10.1016\/j.toxrep.2025.102033_bib39","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.toxrep.2025.102033_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3904\/kjim.2024.135","article-title":"Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer","volume":"40","author":"Kim","year":"2025","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ajcp\/aqae002","article-title":"Immune checkpoint inhibitor\u2013related colitis in patients on immunotherapy for cancer","volume":"162","author":"Sun","year":"2024","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.toxrep.2025.102033_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"13","author":"Albarr\u00e1n","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.toxrep.2025.102033_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jtho.2020.11.005","article-title":"Neurologic complications of immune checkpoint inhibitors in thoracic malignancies","volume":"16","author":"Sechi","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong","year":"2021","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.655283","article-title":"Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of Pembrolizumab","volume":"12","author":"Charabi","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.toxrep.2025.102033_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1108116","article-title":"Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events","volume":"14","author":"M\u00fcller-Jensen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj9672","article-title":"Anti\u2013PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation","volume":"16","author":"Vinnakota","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib48","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.toxrep.2025.102033_bib49","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor\u2013related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.toxrep.2025.102033_bib50","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.toxrep.2025.102033_bib51","doi-asserted-by":"crossref","first-page":"A839","DOI":"10.1210\/jendso\/bvab048.1714","article-title":"Identification of RORg+T cells as key players in thyroid autoimmunity from checkpoint immunotherapy","volume":"5","author":"Lechner","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.toxrep.2025.102033_bib52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.toxrep.2025.102033_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database","volume":"9","author":"Garon-Czmil","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxrep.2025.102033_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.toxrep.2025.102033_bib55","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.toxrep.2025.102033_bib56","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.toxrep.2025.102033_bib57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2217\/imt-2021-0316","article-title":"Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center","volume":"15","author":"Jeun","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.toxrep.2025.102033_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor\u2013induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.toxrep.2025.102033_bib59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.toxrep.2025.102033_bib60","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib61","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib62","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.toxrep.2025.102033_bib63","first-page":"35","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC: CardioOncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib64","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.toxrep.2025.102033_bib65","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","article-title":"Identification of pathogenic immune cell subsets associated with checkpoint inhibitor\u2013induced myocarditis","volume":"146","author":"Zhu","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.toxrep.2025.102033_bib66","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.toxrep.2025.102033_bib67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.toxrep.2025.102033_bib68","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.toxrep.2025.102033_bib69","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib70","first-page":"1187","article-title":"Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Ederhy","year":"2018","journal-title":"JACC: Cardiovasc. Imag."},{"key":"10.1016\/j.toxrep.2025.102033_bib71","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.toxrep.2025.102033_bib72","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.toxrep.2025.102033_bib73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/BOR.0000000000000601","article-title":"Arthritis risk with immune checkpoint inhibitor therapy for cancer","volume":"31","author":"Pundole","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.toxrep.2025.102033_bib74","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/BOR.0000000000000701","article-title":"Treatment of immune checkpoint inhibitor-induced inflammatory arthritis","volume":"32","author":"Jeurling","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.toxrep.2025.102033_bib75","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"McCarter","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.toxrep.2025.102033_bib76","article-title":"Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression","volume":"13","author":"Guo","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.toxrep.2025.102033_bib77","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.toxrep.2025.102033_bib78","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.toxrep.2025.102033_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar8356","article-title":"PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-\u03b21 production","volume":"10","author":"Celada","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2020.12.016","article-title":"Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis","volume":"145","author":"Duchemann","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib81","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.toxrep.2025.102033_bib82","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22906","article-title":"Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor\u2013induced interstitial lung disease among patients with nonlung cancers","volume":"3","author":"Shimoji","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.toxrep.2025.102033_bib83","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1016\/j.cllc.2021.01.014","article-title":"Outcomes of patients with interstitial lung disease receiving programmed cell death 1 inhibitors: a retrospective case series","volume":"22","author":"Dobre","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107351","article-title":"Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer","volume":"184","author":"Murata","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib85","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00432-021-03750-z","article-title":"Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case\u2013control study","volume":"148","author":"Kowalski","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib86","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/intimm\/dxaa022","article-title":"Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease","volume":"32","author":"Suzuki","year":"2020","journal-title":"Int. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib87","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.toxrep.2025.102033_bib88","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib89","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc2728","article-title":"Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding","volume":"5","author":"Andrews","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib90","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2022.40.16_suppl.2504","article-title":"Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)","volume":"40","author":"Falchook","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2019.37.8_suppl.12","article-title":"A phase Ia\/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers","volume":"37","author":"Harding","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib92","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood-2019-128178","article-title":"Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)","volume":"134","author":"Borate","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.toxrep.2025.102033_bib93","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.toxrep.2025.102033_bib94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib95","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10637-012-9866-y","article-title":"A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma","volume":"31","author":"Wang-Gillam","year":"2013","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.toxrep.2025.102033_bib96","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.36_suppl.397600","article-title":"ARC-7: Randomized phase 2 study of domvanalimab +\u2009zimberelimab \u00b1\u2009etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)","volume":"40","author":"Johnson","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib97","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer\u2605","volume":"33","author":"Niu","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib98","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-21-2780","article-title":"A phase 1a\/b open-label, dose-escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors","volume":"28","author":"Mettu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.toxrep.2025.102033_bib99","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1172\/JCI6224","article-title":"Macrophages are a significant source of type 1 cytokines during mycobacterial infection","volume":"103","author":"Wang","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.toxrep.2025.102033_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.152009","article-title":"The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events","volume":"225","author":"Mihic-Probst","year":"2020","journal-title":"Immunobiology"},{"key":"10.1016\/j.toxrep.2025.102033_bib101","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"De Moel","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.toxrep.2025.102033_bib102","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review","volume":"28","author":"Ghosh","year":"2022","journal-title":"J. Clin. Rheuma"},{"key":"10.1016\/j.toxrep.2025.102033_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib104","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-021-03053-9","article-title":"Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies","volume":"71","author":"Seki","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.toxrep.2025.102033_bib105","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","article-title":"Inflammatory markers in autoimmunity induced by checkpoint inhibitors","volume":"147","author":"Husain","year":"2021","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib106","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1\u2013based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.toxrep.2025.102033_bib107","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.intimp.2013.08.012","article-title":"A critical role for interleukin-1\u03b2 in the progression of autoimmune diseases","volume":"17","author":"Zhao","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.toxrep.2025.102033_bib108","doi-asserted-by":"crossref","DOI":"10.1186\/ar2336","article-title":"The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors","volume":"9","author":"De Rham","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.toxrep.2025.102033_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1069999","article-title":"Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2011.06.001","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.toxrep.2025.102033_bib111","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/1348-0421.13067","article-title":"Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma","volume":"67","author":"Miura","year":"2023","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib112","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.toxrep.2025.102033_bib113","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.toxrep.2025.102033_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107461","article-title":"Immune and metabolic checkpoints blockade: dual wielding against tumors","volume":"94","author":"Kazemi","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.toxrep.2025.102033_bib115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"The TRACERx consortium","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.toxrep.2025.102033_bib116","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non\u2013small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.toxrep.2025.102033_bib117","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-catenin activation promotes immune escape and resistance to anti\u2013PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz De Galarreta","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.toxrep.2025.102033_bib118","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.toxrep.2025.102033_bib119","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.toxrep.2025.102033_bib120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.toxrep.2025.102033_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non\u2013small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib122","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS -mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.toxrep.2025.102033_bib123","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2024.01.008","article-title":"SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion","volume":"187","author":"Leuzzi","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.toxrep.2025.102033_bib124","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.toxrep.2025.102033_bib125","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib127","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non\u2013small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.toxrep.2025.102033_bib128","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41598-021-81330-4","article-title":"Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E\/K mutated malignant melanomas","volume":"11","author":"Klein","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxrep.2025.102033_bib129","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1111\/cas.15009","article-title":"Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors","volume":"112","author":"Hirai","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.toxrep.2025.102033_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1185985","article-title":"Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703465","article-title":"A novel oral arginase 1\/2 inhibitor enhances the antitumor effect of PD-1 inhibition in murine experimental gliomas by altering the immunosuppressive environment","volume":"11","author":"Pilanc","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102033_bib132","doi-asserted-by":"crossref","DOI":"10.1186\/s40170-022-00301-z","article-title":"Arginase-1 inhibition reduces migration ability and metastatic colonization of colon cancer cells","volume":"11","author":"Wang","year":"2023","journal-title":"Cancer Metab."},{"key":"10.1016\/j.toxrep.2025.102033_bib133","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cam4.4659","article-title":"Checkpoint inhibitor\/interleukin-based combination therapy of cancer","volume":"11","author":"Mortezaee","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib134","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s12276-024-01301-3","article-title":"Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends","volume":"56","author":"Im","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib136","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00640","article-title":"Predictive impact of tumor mutational burden on real-world outcomes of first-line immune checkpoint inhibition in metastatic melanoma","author":"Andrews","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.toxrep.2025.102033_bib138","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.toxrep.2025.102033_bib139","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib140","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.annonc.2023.05.010","article-title":"Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability","volume":"34","author":"Ratovomanana","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101818","article-title":"Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC","volume":"39","author":"De Marchi","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib142","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e21143","article-title":"LungTS: A new gene expression signature for prediction of response to checkpoint inhibitors in non-small cell lung cancer","volume":"40","author":"De Marchi","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib143","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/life10100219","article-title":"The tumor and host immune signature, and the gut microbiota as predictive biomarkers for immune checkpoint inhibitor response in melanoma patients","volume":"10","author":"Tomela","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.toxrep.2025.102033_bib144","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/cancers13112514","article-title":"Analysis of the gut microbiota: an emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.toxrep.2025.102033_bib145","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.3390\/cancers13194824","article-title":"The gut microbiome and cancer immunotherapy: can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy?","volume":"13","author":"Oh","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.toxrep.2025.102033_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.10.007","article-title":"Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response","volume":"6","author":"Lin","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.toxrep.2025.102033_bib147","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.toxrep.2025.102033_bib148","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib149","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.toxrep.2025.102033_bib151","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.7150\/jca.53242","article-title":"Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study","volume":"12","author":"Egami","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib152","first-page":"689","article-title":"Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor\u2013induced myocarditis","volume":"4","author":"Vasbinder","year":"2022","journal-title":"JACC: CardioOncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib153","article-title":"TNF-\u03b1 inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib154","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.toxrep.2025.102033_bib155","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X221149618","article-title":"Autoantibodies to a nodal isoform of neurofascin in pediatric chronic inflammatory demyelinating polyneuropathy","volume":"10","author":"Chauvet","year":"2023","journal-title":"Child Neurol. Open"},{"key":"10.1016\/j.toxrep.2025.102033_bib156","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001287","article-title":"Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab","volume":"8","author":"Lin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib157","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J. Oncol. Pharm. Pr."},{"key":"10.1016\/j.toxrep.2025.102033_bib158","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtho.2020.09.007","article-title":"Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor\u2013related cholangiohepatitis","volume":"16","author":"Moi","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib159","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib160","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/cncr.34457","article-title":"Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"128","author":"Li","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib161","article-title":"Nivolumab versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: a cost-effectiveness analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.toxrep.2025.102033_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1103055","article-title":"Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxrep.2025.102033_bib163","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s12325-022-02079-4","article-title":"Economic evaluation of sintilimab plus bevacizumab versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma","volume":"39","author":"Zhou","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.toxrep.2025.102033_bib164","article-title":"Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.toxrep.2025.102033_bib165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/cancers14010073","article-title":"Cost-effectiveness of immune checkpoint inhibitors in urothelial carcinoma\u2014a review","volume":"14","author":"Walia","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.toxrep.2025.102033_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2023.102013","article-title":"Cost effectiveness of immune checkpoint inhibitors for treatment of Hepatocellular Carcinoma: a systematic review and Meta-analysis","volume":"51","author":"Dawood","year":"2023","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib167","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.2016.69.6336","article-title":"Cost-effectiveness of immune checkpoint inhibition in BRAF wild-type advanced melanoma","volume":"35","author":"Kohn","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib168","article-title":"Therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and influencing factors","volume":"83","author":"Wu","year":"2021","journal-title":"Ijps"},{"key":"10.1016\/j.toxrep.2025.102033_bib169","series-title":"Immunotherapy","first-page":"97","article-title":"Immunotherapy in NSCLC: A Promising and Revolutionary Weapon","author":"Rolfo","year":"2017"},{"key":"10.1016\/j.toxrep.2025.102033_bib170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib171","doi-asserted-by":"crossref","DOI":"10.1177\/1534735419890020","article-title":"Current clinical progress of PD-1\/PD-L1 immunotherapy and potential combination treatment in non\u2013small cell lung cancer","volume":"18","author":"Li","year":"2019","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.toxrep.2025.102033_bib172","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11523-018-0571-4","article-title":"Avelumab: a review in metastatic merkel cell carcinoma","volume":"13","author":"Shirley","year":"2018","journal-title":"Targ. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib173","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib174","first-page":"381","article-title":"Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma","volume":"84","author":"Mansh","year":"2011","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib175","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6912","article-title":"Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma","volume":"13","author":"Monge","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib176","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1349081","article-title":"Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy","volume":"14","author":"Su","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.toxrep.2025.102033_bib177","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11912-022-01218-y","article-title":"New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors","volume":"24","author":"Gomes De Morais","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.toxrep.2025.102033_bib178","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.20892\/j.issn.2095-3941.2021.0052","article-title":"Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events","volume":"18","author":"Bai","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib179","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib180","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib181","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib182","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti\u2013programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib183","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e14096","article-title":"A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer","volume":"37","author":"Gomes-Lima","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib184","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.3390\/cancers13236141","article-title":"Association between immune-related adverse events and survival in 319 stage IV melanoma patients treated with PD-1-based immunotherapy: an approach based on clinical chemistry","volume":"13","author":"Serna-Higuita","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.toxrep.2025.102033_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.749064","article-title":"Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis","volume":"11","author":"Bastacky","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib186","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxrep.2025.102033_bib187","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1200\/JCO.2018.36.15_suppl.3064","article-title":"Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs)","volume":"36","author":"Riudavets","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib188","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib189","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2019.37.15_suppl.4531","article-title":"Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors","volume":"37","author":"Morales-Barrera","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib190","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/JCO.2019.37.7_suppl.645","article-title":"Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients","volume":"37","author":"Elias","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib191","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2019.37.15_suppl.4116","article-title":"Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy","volume":"37","author":"Das","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.toxrep.2025.102033_bib192","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib193","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.toxrep.2025.102033_bib194","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non\u2013small-cell lung cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.toxrep.2025.102033_bib195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025001519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025001519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:47:52Z","timestamp":1750207672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750025001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":195,"alternative-id":["S2214750025001519"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102033","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors: From friend to foe","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102033"}}